PMID- 28458511
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 11
DP  - 2017
TI  - Prospective, non-interventional, multicenter study of the intraocular 
      pressure-lowering effects of prostaglandin analog/prostamide-containing therapies 
      in previously treated patients with open-angle glaucoma or ocular hypertension.
PG  - 723-731
LID - 10.2147/OPTH.S119963 [doi]
AB  - OBJECTIVE: The objective of this study was to assess the intraocular pressure 
      (IOP)-lowering efficacy, tolerability, safety, and usage patterns of 
      prostaglandin analog/prostamide (PGA/P)-containing topical ocular hypotensives in 
      ocular hypertension (OHT) and primary open-angle glaucoma in the Turkish clinical 
      setting. METHODS: This non-interventional, multicenter study enrolled previously 
      treated patients who failed to achieve target IOP (or experienced unacceptable 
      adverse events [AEs]) and were prescribed a PGA/P-containing IOP-lowering agent. 
      Treatment was initiated at baseline (V1), and patients returned at weeks 4-6 (V2) 
      and 8-12 (V3). The primary efficacy measure was the change in IOP from baseline 
      at V3 in each eye. The secondary measures were physician's assessment of 
      IOP-lowering efficacy, patients (%) reaching target IOP determined at V1, 
      hyperemia score, physician and patient assessment of study treatment tolerability 
      at V3, and AE frequency/severity. A subgroup analysis of patients receiving the 
      most common study treatment was conducted. All analyses were performed using the 
      safety population (patients who received one or more doses and had any data 
      available). RESULTS: Of 358 enrolled patients, 60.6% had primary open-angle 
      glaucoma, 29.9% had secondary open-angle glaucoma (protocol amendment), and 13.1% 
      had OHT; 13 patients had multiple diagnoses. At V3, the mean IOP change from 
      baseline was >/=-4.2 mmHg (>/=21.1%). IOP met or was lower than the target in 81.7% 
      of patients, 95% exhibited none to mild conjunctival hyperemia (most common AE), 
      and tolerability was rated good/very good by >91.1% of patients and physicians. 
      The results were similar in patients who received the most common study 
      treatment, bimatoprost 0.03%/timolol 0.5% (bim/tim; n=310). CONCLUSION: 
      PGA/P-containing medications, including bim/tim, significantly reduced IOP in 
      previously treated patients with open-angle glaucoma or OHT; most reached their 
      target IOP or an IOP even lower than their target and reported good/very good 
      tolerability. PGA/P-containing medications such as bim/tim should be considered 
      as a safe, effective therapeutic option for Turkish patients who exhibit poor 
      response, tolerance, or adherence to their previous therapy.
FAU - Tamcelik, Nevbahar
AU  - Tamcelik N
AD  - Cerrahpasa School of Medicine, Istanbul University.
FAU - Izgi, Belgin
AU  - Izgi B
AD  - Capa School of Medicine, Istanbul University.
FAU - Temel, Ahmet
AU  - Temel A
AD  - Pendik Research and Training Hospital, Marmara University, Istanbul.
FAU - Yildirim, Nilgun
AU  - Yildirim N
AD  - School of Medicine, Osmangazi University, Eskisehir.
FAU - Okka, Mehmet
AU  - Okka M
AD  - Meram School of Medicine, Necmettin Erbakan University, Konya.
FAU - Ozcan, Altan
AU  - Ozcan A
AD  - Faculty of Medicine, Cukurova University, Adana.
FAU - Yuksel, Nursen
AU  - Yuksel N
AD  - Kocaeli University Medical Faculty, Kocaeli.
FAU - Elgin, Ufuk
AU  - Elgin U
AD  - Ulucanlar Eye Hospital, Ankara.
FAU - Altan, Cigdem
AU  - Altan C
AD  - Beyoglu Eye Training and Research Hospital, Istanbul.
FAU - Ozer, Baris
AU  - Ozer B
AD  - Allergan l Iaclari Tic AS, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20170419
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC5402998
OTO - NOTNLM
OT  - bimatoprost
OT  - glaucoma
OT  - ocular hypertension
OT  - prostaglandin analog
OT  - prostamide
OT  - timolol
COIS- Disclosure Baris Ozer is an employee of Allergan plc. The other authors report no 
      conflicts of interest in this work.
EDAT- 2017/05/02 06:00
MHDA- 2017/05/02 06:01
PMCR- 2017/04/19
CRDT- 2017/05/02 06:00
PHST- 2017/05/02 06:00 [entrez]
PHST- 2017/05/02 06:00 [pubmed]
PHST- 2017/05/02 06:01 [medline]
PHST- 2017/04/19 00:00 [pmc-release]
AID - opth-11-723 [pii]
AID - 10.2147/OPTH.S119963 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2017 Apr 19;11:723-731. doi: 10.2147/OPTH.S119963. eCollection 
      2017.